Microparticles in Preeclampsia during Pregnancy: A Systematic Review and
Meta-analysis
Abstract
Background: Preeclampsia (PE) is a severe manifestation of maternal
hypertensive disease with high morbidity and mortality which
microparticles (MPs) might be generated. But there is limited evidence
on response MPs with PE. Objectives: To explore the relationship between
MPs and PE. Search strategy: A systematic review was performed according
to PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) guidelines in Pubmed, Embase, Web of Science and China
National Knowledge Infrastructure (inception to September 20, 2022).
Selection criteria: Studies on patients diagnosed as PE were included.
Studies on patients with chronic hypertension, pre-gestational diabetes
mellitus, and history of recurrent pregnancy loss, renal or hepatic
diseases, and antiphospholipid syndrome were excluded. Data collection
and analysis: Two authors independently screened the studies, extracted
the data and assessed the quality of the studies. Results were combined
descriptively and analyzed using a standardized Excel form. Main
results: We included 25 studies with a total of 1885 patients (862 with
PE and 1023 with healthy pregnancy). Any MPs level was found no
significant difference between PE and healthy pregnant patients in the
second trimester. However, CD31-marked EMPs, RMPs and MPs from placenta
are significantly elevated in the third trimester of preeclampsia, while
CD41-marked PMPs is significantly decreased. After postpartum, tMPs and
EMPs were found no significant difference between PE and healthy
pregnant patients. Conclusion: MPs level is significantly associated
with PE in the third trimester, but the association is dependent on its
cell source and labeled marker.